What’s in NovoCure Limited (NVCR) After Reaching All-Time High?

The stock of NovoCure Limited (NASDAQ:NVCR) reached all time high today, Aug, 15 and still has $95.01 target or 5.00 % above today’s $90.49 share price. This indicates more upside for the $8.88B company. This technical setup was reported by Barchart.com. If the $95.01 PT is reached, the company will be worth $444.20 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 4.77% or $4.12 during the last trading session, reaching $90.49. About 757,016 shares traded. NovoCure Limited (NASDAQ:NVCR) has risen 149.16% since August 15, 2018 and is uptrending. It has outperformed by 149.16% the S&P500.

Analysts await NovoCure Limited (NASDAQ:NVCR) to report earnings on October, 24. They expect $-0.02 earnings per share, up 84.62 % or $0.11 from last year’s $-0.13 per share. After $-0.01 actual earnings per share reported by NovoCure Limited for the previous quarter, Wall Street now forecasts 100.00 % negative EPS growth.

NovoCure Limited (NASDAQ:NVCR) Ratings Coverage

Among 3 analysts covering NovoCure (NASDAQ:NVCR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. NovoCure has $9100 highest and $50 lowest target. $73.75’s average target is -18.50% below currents $90.49 stock price. NovoCure had 9 analyst reports since March 20, 2019 according to SRatingsIntel. JP Morgan downgraded the shares of NVCR in report on Friday, July 26 to “Neutral” rating. The rating was maintained by Mizuho with “Buy” on Friday, July 26.

More notable recent NovoCure Limited (NASDAQ:NVCR) news were published by: Fool.com which released: “5 Key Takeaways From NovoCure’s Big First Quarter – Motley Fool” on May 07, 2019, also Seekingalpha.com with their article: “NovoCure Limited 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” published on July 25, 2019, Nasdaq.com published: “Noteworthy Thursday Option Activity: SALT, PTC, NVCR – Nasdaq” on July 11, 2019. More interesting news about NovoCure Limited (NASDAQ:NVCR) were released by: Nasdaq.com and their article: “Why NovoCure Stock Jumped 20.5% in May – Nasdaq” published on June 06, 2019 as well as Nasdaq.com‘s news article titled: “NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates – Nasdaq” with publication date: July 25, 2019.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $8.88 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

NovoCure Limited (NASDAQ:NVCR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.